Pharma BD Deal Intelligence

Novartis AG / Legend Biotech Corporation

2023 · Licensing/Option · $1.1B · Complete

Announcement Sentiment

100

Strongly positive

Outcome Score

Largely worked — most objectives met.

Novartis licensed Legend Biotech's DLL3-targeting CAR-T cell therapies including LB2102, with Novartis gaining exclusive worldwide development and commercialization rights.

Key facts

Announced Nov 13, 2023
Closed Dec 28, 2023
Deal value $1.1B
Deal type Licensing/Option
Therapeutic area Gene Therapy, Oncology
Indications Small cell lung cancer
Key assets LB2102
Mechanism CAR-T cell therapy (anti-DLL3)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals